Sequential change of asymmetric dimethylarginine levels after initiation of peritoneal dialysis in patients with end-stage renal disease

Nephrology

Volumn 15, Issue 6, 2010, Pages 639-643

  Lee, Kwan Hyun ^a   Gil, Hyo Wook ^a   Yang, Jong Oh ^a   Lee, Eun Young ^a   Hong, Sae Yong ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

asymmetric dimethylarginine; normalized protein catabolic rate; peritoneal dialysis

Indexed keywords

CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN; N(G),N(G) DIMETHYLARGININE; SERUM ALBUMIN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; UREA NITROGEN BLOOD LEVEL;

AGED; ARGININE; BIOLOGICAL MARKERS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956193663     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01272.x     Document Type: Article

References (25)

1. Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S. Asymmetric dimethylarginine (adma) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin. Exp. Nephrol. 2007 11 : 115 121.
2. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 2001 358 : 2113 2117.
3. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest. 1997 100 : 2153 2157.
4. Kakimoto Y, Akazawa S. Isolation and identification of n-g,n-g- and n-g,n'-g-dimethyl-arginine, n-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J. Biol. Chem. 1970 245 : 5751 5758.
5. Yin QF, Xiong Y. Pravastatin restores ddah activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J. Cardiovasc. Pharmacol. 2005 45 : 525 532.
6. Stuhlinger MC, Tsao PS, Her JH et al. Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine. Circulation 2001 104 : 2569 2575.
7. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am. J. Physiol. Renal Physiol. 2008 294 : F1 F9.
8. Harty JC, Boulton H, Curwell J et al. The normalized protein catabolic rate is a flawed marker of nutrition in capd patients. Kidney Int. 1994 45 : 103 109.
9. Kopple JD. Pathophysiology of protein-energy wasting in chronic renal failure. J. Nutr. 1999 129 : 247S 251S.
10. Siroka R, Trefil L, Rajdl D, Racek J, Cibulka R. Asymmetric dimethylarginine - Comparison of hplc and elisa methods. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007 850 : 586 587.
11. Twardowski Z, Nolph KO, Khanna R et al. Peritoneal equilibration test. Perit. Dial. Int. 1987 7 : 138.
12. Kopple JD, Gao XL, Qing DP. Dietary protein, urea nitrogen appearance and total nitrogen appearance in chronic renal failure and capd patients. Kidney Int. 1997 52 : 486 494.
13. Achan V, Broadhead M, Malaki M et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol. 2003 23 : 1455 1459.
14. Fickling SA, Holden DP, Cartwright JE, Nussey SS, Vallance P, Whitley GS. Regulation of macrophage nitric oxide synthesis by endothelial cells: A role for ng,ng-dimethylarginine. Acta Physiol. Scand. 1999 167 : 145 150.
15. Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (adma). Clin. Nutr. 2003 22 : 17 22.
16. Nijveldt RJ, Siroen MP, van der Hoven B et al. High plasma arginine concentrations in critically ill patients suffering from hepatic failure. Eur. J. Clin. Nutr. 2004 58 : 587 593.
17. Ogawa T, Kimoto M, Sasaoka K. Dimethylarginine : Pyruvate aminotransferase in rats. Purification, properties, and identity with alanine : Glyoxylate aminotransferase 2. J. Biol. Chem. 1990 265 : 20938 20945.
18. Wang J, Sim AS, Wang XL, Wilcken DE. L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (hepg2) cells. Cell Mol. Life Sci. 2006 63 : 2838 2846.
19. Ogawa T, Kimoto M, Watanabe H, Sasaoka K. Metabolism of ng,ng-and ng,n'g-dimethylarginine in rats. Arch. Biochem. Biophys. 1987 252 : 526 537.
20. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992 339 : 572 575.
21. Kielstein JT, Boger RH, Bode-Boger SM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol. 1999 10 : 594 600.
22. Anderstam B, Katzarski K, Bergstrom J. Serum levels of ng, ng-dimethyl-l-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J. Am. Soc. Nephrol. 1997 8 : 1437 1442.
23. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 2000 58 : 1261 1266.
24. Kielstein JT, Bode-Boger SM, Frolich JC, Haller H, Boger RH. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int. Suppl. 2001 78 : S9 S13.
25. Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Tager M, Bode-Boger SM. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: Role of dimethylarginine dimethylaminohydrolase. J. Am. Soc. Nephrol. 2005 16 : 892 898.